Evidence map›Paper›PMID 21252059›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2011

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.

E D Jacobsen, H T Kim, V T Ho, C S Cutler, J Koreth, D C Fisher, P Armand, E P Alyea, A S Freedman, R J Soiffer and 1 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. How to Sequence Therapies in Peripheral T Cell Lymphoma.Current treatment options in oncology · 2021
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Update on the Treatment of Anaplastic Large Cell Lymphoma.Current hematologic malignancy reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

E D JacobsenDepartment of Medical Oncology. Electronic address: edjacobsen@partners.org.
H T KimDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, USA.
V T HoDepartment of Medical Oncology.
C S CutlerDepartment of Medical Oncology.
J KorethDepartment of Medical Oncology.
D C FisherDepartment of Medical Oncology.
P ArmandDepartment of Medical Oncology.
E P AlyeaDepartment of Medical Oncology.
A S FreedmanDepartment of Medical Oncology.
R J SoifferDepartment of Medical Oncology.
J H AntinDepartment of Medical Oncology.
Boston University · USHealthCare Partners Medical Group · US

Funding

Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5M
NCI NIH HHS CA142106NCI NIH HHS P01 CA142106
6 · The paper itself

Abstract

backgroundThe prognosis for patients with most forms of T-cell lymphoma is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome. PATIENTS AND

methodsThis study examines the outcome of 52 patients who underwent ablative or nonablative allogeneic HSCT for peripheral T-cell lymphoma (PTCL) or advanced mycosis fungoides/Sezary syndrome over a 12-year period at a single institution. We divided the patients into those with predominantly nodal histologies: peripheral T-cell not otherwise specified (PTCL NOS), angioimmunoblastic (AITL), or anaplastic large cell lymphoma, T/null type (systemic) (ALCL), and predominantly extranodal histologies: natural killer (NK)/T cell, enteropathy type, hepatosplenic, subcutaneous panniculitic, mycosis fungoides, or T cell or NK cell other.

resultsMedian follow-up of survivors is 49 months. Non-relapse mortality and relapse at 3 years was 27% and 43%, respectively. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 21%. The incidence of extensive chronic GVHD at 2 years was 27%. The 3-year progression-free survival was 30%: 45% in patients with predominantly nodal histologies (PTCL NOS, AITL, and ALCL) and 6% in patients with predominantly extranodal histologies (P = 0.016). Overall survival at 3 years was 41% for all patients.

conclusionAllogeneic HSCT can produce long-term remissions in relapsed/refractory T-cell lymphoma, especially those with nodal histologies.

Indexed as

Stem Cell TransplantationAdultAgedFemaleFollow-Up StudiesGraft vs Host DiseaseHumansLymphoma, T-Cell, PeripheralMaleMiddle AgedMycosis FungoidesSezary SyndromeSkin NeoplasmsSurvival RateTransplantation, HomologousTreatment Outcome

Identifiers

PMID21252059
PMCPMC3121969
OpenAlexW2158739966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.